Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Amgen
- Study ID
- NCT07297979
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Ewing Sarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Xaluritamig — DRUGParticipants will receive xaluritamig via short-term intravenous (IV) infusion.
Study Details
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.
Key Dates
- Start date
- Apr 8, 2026
- Status verified
- Jun 2026
- Primary completion
- May 26, 2030
- Completion
- May 26, 2030
Study Design
- Enrollment
- 50 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Part 1 (Dose Confirmation)Part 1 will begin with a pre-specified xaluritamig target dose and frequency. Multiple dose levels and/or alternative dose regimens may be explored in parallel to determine 1 or more recommended doses for expansion, which is/are considered safe, based on emerging data.
- Experimental: Part 2 (Dose Expansion)Participants will be treated in Part 2 after the recommended doses for expansion for xaluritamig are determined in Part 1 to further characterize preliminary antitumor activity and safety.
Primary Outcome Measure
Number of Participants Experiencing a Dose-limiting Toxicity (DLT) (Part 1 Only) [ Time Frame: Up to 42 days ]
Central Contacts
- Amgen Call Center866-572-6436
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | - |
| University of California Los Angeles | Los Angeles | California | 90995-1752 | - |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | - |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | - |
Find similar trials in Los Angeles, CA
Related Studies
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasPHASE1 · Recruiting · Inhibrx Biosciences, Inc · Scottsdale, Arizona
- Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS MalignanciesPHASE1 · Recruiting · New York Medical College · Valhalla, New York
- Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing SarcomaPHASE1/PHASE2 · Recruiting · Jazz Pharmaceuticals · Los Angeles, California
- Lurbinectedin in FET-Fused TumorsPHASE1/PHASE2 · Recruiting · Children's Hospital of Philadelphia · Los Angeles, California